A NSW Government website


AW Morrow Gastroenterology and Liver Centre Research

The AW Morrow Gastroenterology and Liver Centre has a strong and robust research base. Key research strengths include Hepatology, Liver Transplant, Hepatocellular Carcinoma, Inflammatory Bowel Disease, Colorectal and Endoscopy.

Our Research Themes at the Laboratory Level

The role of liver stem cells in liver disease This work is lead by Professor McCaughan and has defined a novel characteristic of liver stem cells within the inflammatory/fibrotic niche that develops during chronic liver disease and cirrhosis.  This work has found that a cellular structure, called the primary cilium, transduces signals from the local environment to the liver stem cell compartment leading to proliferation and migration of cells.  One of the key mediators is the hedgehog molecule and we have defined this hedgehog pathway and the response of these cells in mouse liver models.  We have confirmed these findings in human liver disease and are now working in collaboration with the Cellular and Molecular Regenerative Institute at Edinburgh University to grow organoids and are using a unique mouse model to explore the exact function of these signals.  These cells can repopulate an injured liver and replace hepatocytes, significantly improving liver function.

The role of molecular pathways in primary liver cancer


This work has been exploring pathogenic pathways in hepatocellular cancer and more recently biliary cancer.  This research includes reduced liver cancer development in knockout mice for SP1 and SP2  and microRNA 181a. Currently, in close collaboration with Dr Maintain Palendira in the Charles Perkins Centre at the University of Sydney, we are using tissue Immune mass cytometry to explore cell-cell interactions within human liver cancer tissues . This is the only attempt to do this in Australia as we have access to one of only two machines capable of providing this technology. We are able to label cells with over thirty unique antibodies to detect complex cell subsets that are undetectable using usual approaches. 

Recently we have developed a unique mouse model of primary biliary cancer which has similarities to human disease. We have also used new strategies that target the tumour endothelium and the tumour associated immune infiltrate in experimental models. We believe that such multiple approaches to liver cancer is crucial to understand the complex nature of the problem and to produce new effective therapeutics. 

The role of the Oligopeptidase Gene family in liver diseases and cancer This work is lead by Professor Mark Gorrell and has made major breakthroughs in the study of Type II Diabetes associated with liver disease, liver cancer and also liver fibrosis.  The work has been able to show that the serum Fibroblast Activation Protein (FAP) is able to show how liver transplants are spontaneously accepted and the potential to select humans for immunosuppressive withdrawal.  The work has identified that liver cytotoxic T cells which would normally reject and damage the liver are eliminated by the liver in the early phases of transplantation by a normal mechanism whereby liver cells actually eat the activated immune cells.  The process has been named by us as suicidal empiriopolesis.  The work also increases our understanding of how viruses and autoimmune liver diseases are associated with progression to chronicity and non-resolution of disease.
In collaboration with Professor Heath at the Walter and Eliza Hall Institute in Melbourne, Dr Bertolino has furthermore identified blood memory cells that reside in the liver.  These cells are very efficient in protecting against malaria infection and this potentially provides new strategies to protect individuals against pathogens that attack the liver such as malaria and other viruses.  More recently, a novel type of macrophage cell has been discovered by Dr Bertolino's group, where a novel liver macrophage which is located in the liver capsule is currently under examination for playing a role in protecting the liver against pathogenic effects from the peritoneal cavity. Professor McCaughan has been part of an international consortium that has developed molecular signatures for human liver allograft rejection and injury that is already helping in treatment decision making following liver transplantation in our patients. 

Our Research Themes at the Clinical Level

New therapies for Hepatitis B and C 


New HCV therapies are one of the most exciting advances in the whole of medicine for many years leading the potential to eventually eradicate HCV infection worldwide. We have significant community care nurse lead programs to deliver these therapies to the wider HCV infected populations.

Chief Investigator studies in Australia have lead to the use of the new Hepatitis C treatments in patients with liver failure and undergoing liver transplantation. For the first time we have seen reversibility of HCV related liver failure resulting in a decrease in the need for transplantation in these patients.  

Professor McCaughan and Associate Professor Strasser have also been active participants and leaders in the International Liver Transplant Society consensus statements for the treatment and management of hepatitis C. Treatment outcomes in First nations peoples have also been investigated and outcomes published.

New therapies are emerging to cure HBV infection and we have been involved in those studies .Furthermore we have participated in the development of national and Asian pacific  consensus guidelines for the management of hepatitis B infection.

New therapies for Hepatocellular Cancer (HCC)


HCC accounts for the vast majority of primary liver cancers, representing the 4th leading cause of cancer-related death worldwide. The WHO has estimated that >1 million people will die from liver cancer in 2030. Despite recent advances, 5-year survival remains dismal at <20%.  In Australia HCC is the fastest growing solid cancer apart from thyroid cancer.

We have been involved in key studies that have examined the outcomes of HCC therapies in national studies. Outcomes of HCC in our liver transplant patients have also been studied together with quality care parameters through a national consensus process.

In a collaborative study with St George Hospital and UNSW we have been studying the role of the microbiome in HCC patients associated with fatty liver diseases and have described outcomes of patients with non - viral associated HCC. 

Improving Outcomes for patients with advanced liver disease This population has a high mortality and an increasing need for improved therapies. Dr Avik Majumdar and Dr Ken Liu, together with our dieticians Helen Vidot and Joanne Heyman, have lead studies involving nutritional intervention including developing sarcopenia and frailty guidelines for intervention in gastrointestinal bleeding, treatment of infections together with management of hepatic encephalopathy and ascites. Furthermore, we have been investigating the use of non-invasive markers for the diagnosis of cirrhosis.
Outcomes in Primary Sclerosing Cholangitis (PSC) and drug induced liver injury Our patients with PSC and inflammatory bowel disease were  analysed in the largest Australian study of PSC and has lead to a national outcomes study including studies of the microbiome. We have published a large study of drug induced severe liver injury indicating that  herbal medicines play a major role in these cases.
Endoscopy research
  • Colonoscopy guidelines 
  • New therapy for leaks and perforations of the bowel
  • New therapy for achalasia, the new POEM procedure
  • Double balloon ERCP to treat biliary strictures in patients without a native bile duct
  • New techniques to biopsy the biliary tree 
  • Endoscopic ultrasound (EUS) procedures to diagnose and treat intra-abdominal collections, tumours and pancreatic cysts
  • Use of EUS to drain the biliary system 
  • Development of a screening protocol for development of pancreatic cancer
Inflammatory bowel disease research
  • Clinical trials for new therapies in Ulcerative Colitis and Inflammatory Bowel Disease
  • Detection of pre cancer lesions in IBD
  • Guidelines for the use of biological agents 
Outcomes in liver transplantation includes the following studies
  • Outcomes following the use of split liver techniques in liver transplantation 
  • Prolonged function of human livers in machine perfusion devises 
  • Development of new scoring systems for the allocation of livers for patients on the liver transplant waiting list

Selected Grants

Amount awarded Grant and project details
$4,000,000 Cancer Institute NSW, 2021-2026
The APRICA  program - Accelerated translational research in Liver Cancer
RPA Investigator: McCaughan G (CIB)
$3,989,422 MRFF, 2021-2025
Improving Diagnosis in Cancers with Low Survival Rates : Microbial based biomarkers powered by artificial intelligence for early detection of liver cancer in Australia. The Australian Liver Cancer Microbiome Consortium.
RPA Chief Investigator: McCaughan G
$1,800,000 Australian Cancer Research Foundation, 2022-2026
ACRF Molecular Theranostics Laboratory
Investigators: Hogg PJ, Simes J, Stockler M, Gorrell M, McCaughan G, Codd R. 
$450,000 Cancer Council NSW Project Grant, 2020-2022
New therapies for Liver Cancer
Investigators: McCaughan G, Chen J

Our Publications


Barreto SG, Strasser SI, McCaughan GW, Fink MA, Jones R, McCall J, Munn S, Macdonald GA, Hodgkinson P, Jeffrey GP, Jaques B, Crawford M, Brooke-Smith ME, Chen JW. Expansion of Liver Transplantation Criteria for Hepatocellular Carcinoma from Milan to UCSF in Australia and New Zealand and Justification for Metroticket 2.0. Cancers (Basel). 2022 Jun 3;14(11):2777. doi: 10.3390/cancers14112777.
Bart NK, Liu K, Kotlyar E, Keogh AM. Portopulmonary Hypertension: The Interplay Between the Liver and Pulmonary Arteries. Heart Lung Circ. 2022 Sep;31(9):1185-1187. doi: 10.1016/j.hlc.2022.07.010.
Beumer BR, van Vugt JLA, Sapisochin G, Yoon P, Bongini M, Lu D, Xu X, De Simone P, Pintore L, Golse N, Nowosad M, Bennet W, Tsochatzis E, Koutli E, Abbassi F, Claasen MPAW, Merli M, O'Rourke J, Gambato M, Benito A, Majumdar A, Tan EK, Ebadi M, Montano-Loza AJ, Berenguer M, Metselaar HJ, Polak WG, Mazzaferro V, IJzermans JNM; Collaborators. Impact of muscle mass on survival of patients with hepatocellular carcinoma after liver transplantation beyond the Milan criteria. J Cachexia Sarcopenia Muscle. 2022 Oct;13(5):2373-2382. doi: 10.1002/jcsm.13053. Epub 2022 Aug 10.
Bonnichsen M, Stoklosa T, Bowen D, Majumdar A. Safety first, a harmful interaction between rivaroxaban and berberine. Intern Med J. 2022 May;52(5):887-888. doi: 10.1111/imj.15774.
Brown RS Jr, Collins MA, Strasser SI, Emmett A, Topp AS, Burroughs M, Ferreira R, Feld JJ. Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients with Evidence of Portal Hypertension. Infect Dis Ther. 2022 Apr;11(2):913-924. doi: 10.1007/s40121-022-00599-8. Epub 2022 Feb 17.
Cassandra R. Harapas, Kim S. Robinson, Kenneth Lay, Jasmine Wong, Ricardo Moreno Traspas, Nasrin Nabavizadeh, Annick Rass-Rothschild, Bertrand Boisson, Scott B. Drutman, Pawat Laohamonthonkul, Devon Bonner, Jingwei Rachel Xiong, Mark D. Gorrell, Sophia Davidson, Chien-Hsiung Yu, Mark D. Fleming, Jonas Gudera, Jerry Stein, Miriam Ben-Harosh, Emily Groopman, Akiko Shimamura, Hannah Tamary, Hülya Kayserili, Nevin Hatipoğlu, Jean-Laurent Casanova, Jonathan A. Bernstein, Franklin L. Zhong, Seth L. Masters, Bruno Reversade 2022 DPP9 deficiency: An inflammasomopathy that can be rescued by lowering NLRP1/IL-1 signaling. Science Immunology 7(75):eabi4611. doi:10.1126/sciimmunol.abi4611 (IF 17.73) 
Chen J, Cheng NC, Boland J, Liu K, Kench J, Watkins DN, Ferrira-Gonzalez S, Forbes SJ, McCaughan GW. Deletion of kif3a in CK19 positive cells leads to primary cilia loss, biliary cell proliferation and cystic liver lesions in TAA-treated mice. Biochim Biophys Acta Mol Basis Dis. 2022;1868:166335. 
Chen J, Zhao Y, Zhang F, Li J, Boland JA, Cheng NC, Liu K, Tiffen JC, Bertolino P, Bowen DG, Krueger A, Lisowski L, Alexander IE, Vadas MA, El-Omar E, Gamble JR, McCaughan GW. Liver-specific deletion of miR-181ab1 reduces liver tumour progression via upregulation of CBX7. Cell Mol Life Sci. 2022 Jul 22;79(8):443. doi: 10.1007/s00018-022-04452-6.
Chetwood JD, Koorey D, Bryant C. Hyperammonaemic encephalopathy. Intern Med J. 2022 Apr;52(4):693-694. doi: 10.1111/imj.15738.
Chetwood JD, Popuri R, Majumdar A, Saxena P. All in all, not just a clip on the wall. Dig Liver Dis. 2022 Oct;54(10):1437-1438. doi: 10.1016/j.dld.2022.03.010. Epub 2022 Apr 6.
Chetwood JD, Shin JS, Koorey D Gastrointestinal: Esophageal nodularity in a 32-year-old female patient. [Review] Journal of Gastroenterology & Hepatology. 37(10):1840, 2022 10.
Chetwood JD, Volovets A, Sivam S, Koh C. Surgical considerations in cystic fibrosis: what every general surgeon needs to know. ANZ J Surg. 2022 Oct;92(10):2425-2432. doi: 10.1111/ans.17948. Epub 2022 Aug 3.PMID: 35920692 Free PMC article. Review.
Chetwood JD, Wells MG, Tsoutsman T, Pulitano C, Crawford MD, Liu K, Strasser SI, McCaughan GW, Majumdar A. MELD-GRAIL and MELD-GRAIL-Na Are Not Superior to MELD or MELD-Na in Predicting Liver Transplant Waiting List Mortality at a Single-center Level. Transplant Direct. 2022 Jun 10;8(7):e1346. doi: 10.1097/TXD.0000000000001346. eCollection 2022 Jul
Clark PJ, Valery PC, Strasser SI, Weltman M, Thompson AJ, Levy M, Leggett B, Zekry A, Rong J, Angus P, George J, Bollipo S, McGarity B, Sievert W, Macquillan G, Tse E, Nicoll A, Wade A, Chu G, Harding D, Cheng W, Farrell G, Roberts SK. Liver Disease and Poor Adherence Limit Hepatitis C Cure: A Real-World Australian Treatment Cohort. Dig Dis Sci. 2022 May 13. doi: 10.1007/s10620-022-07483-y. Online ahead of print.
Clark PJ, Valery PC, Ward J, Strasser SI, Weltman M, Thompson A, Levy MT, Leggett B, Zekry A, Rong J, Angus P, George J, Bollipo S, McGarity B, Sievert W, Macquillan G, Tse E, Nicoll A, Wade A, Chu G, Harding D, Cheng W, Farrell G, Roberts SK. Hepatitis C treatment outcomes for Australian First Nations Peoples: equivalent SVR rate but higher rates of loss to follow-up. BMC Gastroenterol. 2022 Jul 11;22(1):339. doi: 10.1186/s12876-022-02416-5.
Coupland H, Day C, Haber P, Pritchard-Jones J, McKee K, George J, McCaughan G. Client resistance to hepatitis C treatment initiation in opioid agonist treatment clinics in Sydney, Australia: A qualitative study. Drug Alcohol Rev. 2022 Mar;41(3):706-714. doi: 10.1111/dar.13414. Epub 2021 Nov 28.
De Martin E, Londoño MC, Emamaullee J, Lerut J, Potts J, Aluvihare V, Spiro M, Raptis DA, McCaughan G;. The optimal immunosuppression management to prevent early rejection after liver transplantation: A systematic review of the literature and expert panel recommendations. Clin Transplant. 2022 Oct;36(10):e14614. doi: 10.1111/ctr.14614. Epub 2022 Feb 24.
Dennis C, Prince DS, Moayed-Alaei L, Remash D, Carr-Boyd E, Bowen DG, Strasser SI, Crawford M, Pulitano C, Kench J, McCaughan GW, McKenzie C, Liu K. Association between vessels that encapsulate tumour clusters vascular pattern and hepatocellular carcinoma recurrence following liver transplantation. Front Oncol. 2022 Oct 26;12:997093. doi: 10.3389/fonc.2022.997093. eCollection 2022.
English K, Tan SY, Kwan R, Holz LE, Sierro F, McGuffog C, Kaisho T, Heath WR, MacDonald KP, McCaughan GW, Bowen DG, Bertolino P. The liver contains distinct interconnected networks of CX3CR1+ macrophages, XCR1+ type 1 and CD301a+ type 2 conventional dendritic cells embedded within portal tracts. Immunol Cell Biol. 2022 Jul;100(6):394-408. doi: 10.1111/imcb.12559. Epub 2022 Jun 19.
Gill M, Majumdar A. Editorial: optimising hepatitis B vaccine response in inflammatory bowel disease-time to get some skin in the game. Aliment Pharmacol Ther. 2022 Jul;56(2):353-354. doi: 10.1111/apt.17044.
Grootveld A, Kyaw W, Panova V, Lau A; Ashwin E, Seuzaret G, Dhenni R, Bhattacharyya, Hua Khoo W, Biro M, Mitra T, Meyer-Hermann M, Bertolino P, TanakaM,  Hume D,  Croucher P, Brink R, Nguyen A, Bannard O, Phan TG.Locally activated tingible body macrophages use cellular processes to chase and capture motile apoptotic cell fragments in the germinal centre. Cell in Press (IF 66.85).
Gu B, Venkatesh K, Williams AJ, Ng W, Corte C, Gholamrezaei A, Ghaly S, Xuan W, Paramsothy S, Connor S. Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn's disease. World J Gastroenterol. 2022 Jun 21;28(23):2597-2608. doi: 10.3748/wjg.v28.i23.2597.PMID: 35949350 Free PMC article.
Hall SAL, Burns GS, Anagnostou D, Vogrin S, Sundararajan V, Ratnam D, Levy MT, Lubel JS, Nicoll AJ, Strasser SI, Sievert W, Desmond PV, Ngu MC, Angus P, Sinclair M, Meredith C, Matthews G, Revill PA, Jackson K, Littlejohn M, Bowden DS, Locarnini SA, Visvanathan K, Thompson AJ. Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels. Aliment Pharmacol Ther. 2022 Jul;56(2):310-320. doi: 10.1111/apt.16968. Epub 2022 May 6.
Hall SAL, Burns GS, Mooney BJ, Millen R, Morris R, Vogrin S, Sundararajan V, Ratnam D, Levy MT, Lubel JS, Nicoll AJ, Strasser SI, Sievert W, Desmond PV, Ngu MC, Angus P, Sinclair M, Meredith C, Matthews G, Revill PA, Jackson K, Littlejohn M, Bowden S, Locarnini SA, Thompson AJ, Visvanathan K. Hepatitis B Virus Flares After Nucleot(s)ide Analogue Cessation Are Associated With Activation of Toll-Like Receptor Signaling Pathways. J Infect Dis. 2022 Dec 28;227(1):123-132. doi: 10.1093/infdis/jiac375.
Howell J, Majumdar A, Fink MA, Byrne M, McCaughan G, Strasser SI, Crawford M, Hodgkinson P, Stuart KA, Tallis C, Chen J, Wigg A, Jones R, Jaques B, Jeffrey G, Adams L, Wallace MC, Munn S, Gane E, Thompson AJ, Gow P. Turning the Tide on Hepatitis C Virus-Related Liver Transplantation: The Return on Investment in Hepatitis C Virus Treatment in Australia and New Zealand. Liver Transpl. 2022 Feb;28(2):236-246. doi: 10.1002/lt.26329. Epub 2021 Nov 10.
Howell J, Van H, Pham M, Sawhney R, Li F, Bhat P, Lubel J, Kemp W, Bloom S, Majumdar A, McCaughan G, Hall S, Spelman T, Doyle JS, Hellard M, Visvanathan K, Thompson AJ, Drummer HE, Anderson D. Validation of novel point-of-care test for alanine aminotransferase measurement: A pilot cohort study. Clin Liver Dis (Hoboken). 2022 Oct 10;20(4):136-139. doi: 10.1002/cld.1261. eCollection 2022 Oct.
Jacob R, Liu K, Marinelli T. Successful liver transplantation for hepatitis B-related acute liver failure in a patient with active COVID-19. Transpl Infect Dis. 2022 Aug;24(4):e13889. doi: 10.1111/tid.13889. Epub 2022 Jul 9.
Jing Ren, Xiaoyu Wang, Christine Yee, Mark D. Gorrell, Susan V. McLennan, Stephen M. Twigg 2022 Sitagliptin is more effective than Gliclazide in Preventing Pro-Fibrotic and Pro-Inflammatory Changes in a Rodent model of Diet-Induced Non-Alcoholic Fatty Liver Disease (NAFLD). Molecules 27(3):727.  Doi 10.3390/molecules27030727  PMID 35163991 
Jing Ren, Xiaoyu Wang, Sarah Parry, Christine Yee, Mark D. Gorrell, Susan V. McLennan, Stephen M. Twigg 2022 Targeting CCN2 Protects Against Progressive Non-Alcoholic Steatohepatitis in a Preclinical Model Induced by High-Fat Feeding and Type 2 Diabetes. Journal of Cell Communication and Signaling -  E-Pub 22.1.22  doi 10.1007/s12079-022-00667-1. PMID 35038159. 
Khan S, Gilhotra R, Di Jiang C, Rowbotham D, Chong A, Majumdar A, White C, Huelsen A, Brooker J, O'Beirne J, Schauer C, Efthymiou M, Vaughan R, Chandran S. The role of a novel self-expanding metal stent in variceal bleeding: a multicenter Australian and New Zealand experience. Endosc Int Open. 2022 Mar 14;10(3):E238-E245. doi: 10.1055/a-1729-0104. eCollection 2022 Mar.
Kynaston A, Liu K, Davis A, Kao S, McKenzie C. A case of steroid-responsive nivolumab-induced cholangitis. Pathology. 2022; 54:820-823 
Lau G, Yu ML, Wong G, Thompson A, Ghazinian H, Hou JL, Piratvisuth T, Jia JD, Mizokami M, Cheng G, Chen GF, Liu ZW, Baatarkhuu O, Cheng AL, Ng WL, Lau P, Mok T, Chang JM, Hamid S, Dokmeci AK, Gani RA, Payawal DA, Chow P, Park JW, Strasser SI, Mohamed R, Win KM, Tanwandee T, Sarin SK, Omata M. Correction to: APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. Hepatol Int. 2022 Apr;16(2):486-487. doi: 10.1007/s12072-022-10301-2. Epub 2022 Jan 25.
Lau NS, Ly M, Dennis C, Liu K, Kench J, Crawford M, Pulitano C.Artif Organs. Long-term normothermic perfusion of human livers for longer than 12 days. 2022 Dec;46(12):2504-2510. doi: 10.1111/aor.14372. Epub 2022 Aug 5.
Lau NS, Ly M, Liu K, Majumdar A, Strasser SI, Biswas RK, McCaughan GW, Crawford M, Pulitano C. Is it safe to expand the indications for split liver transplantation in adults? A single-center analysis of 155 in-situ splits. Clin Transplant. 2022 Jul;36(7):e14673. doi: 10.1111/ctr.14673. Epub 2022 Apr 26.
Lin A, Wong K, Visser SK, Jo H, Al-Hindawi Y, Kosbab-Jackson K, Cocks M, Volovets A, Haber P, Hammond K, Taylor N, Yozghatlian V, Lau EM, Marshall NS, Aquino-Salomon T, Sivam S. Diagnosis of cystic fibrosis in adults: Australian Cystic Fibrosis Data Registry data, 2000-2019. Med J Aust. 2022 Dec 1. doi: 10.5694/mja2.51797. Online ahead of print.
Lin H, Cheuk-Yan Yiu D, Chin S, Liu K, Cheuk-Fung Yip T. Metformin in patients with hepatocellular carcinoma receiving immunotherapy.J Hepatol. 2022 Dec 23:S0168-8278(22)03463-8. doi: 10.1016/j.jhep.2022.12.011. Online ahead of print.PMID: 36572351
Liu K, Yip TCF, Masson S, Fateen W, Schwantes-An TH, McCaughan GW, Morgan TR, Aithal GP, Seth D. Validation of the aMAP score to predict hepatocellular carcinoma development in a cohort of alcohol-related cirrhosis patients. Liver Cancer Int. 2022;3:99-104
Liu XT, Chung LH, Liu D, Chen J, Huang Y, Teo JD, Han XD, Zhao Y, Guan FHX, Tran C, Lee JY, Couttas TA, Liu K, McCaughan GW, Gorrell MD, Don AS, Zhang S, Qi Y. Ablation of sphingosine kinase 2 suppresses fatty liver-associated hepatocellular carcinoma via downregulation of ceramide transfer protein. Oncogenesis. 2022 Nov 4;11(1):67. doi: 10.1038/s41389-022-00444-0.
Lubel JS, Strasser SI, Thompson AJ, Cowie BC, MacLachlan J, Allard NL, Holmes J, Kemp WW, Majumdar A, Iser D, Howell J, Matthews GV. Australian consensus recommendations for the management of hepatitis B. Med J Aust. 2022 May 16;216(9):478-486. doi: 10.5694/mja2.51430. Epub 2022 Mar 6.
Ly M, Lau NS, McKenzie C, Kench JG, McCaughan G, Crawford M, Pulitano C. The Delay of Arterialization After Initial Portal Reperfusion More Than Warm Ischemia Time May Determine Ischemic-type Biliary Injury. Transplantation. 2022 Feb 1;106(2):e167-e168. doi: 10.1097/TP.0000000000003936.
Madill-Thomsen KS, Abouljoud M, Bhati C, Ciszek M, Durlik M, Feng S, Foroncewicz B, Francis I, Grąt M, Jurczyk K, Klintmalm G, Krasnodębski M, McCaughan G, Miquel R, Montano-Loza A, Moonka D, Mucha K, Myślak M, Pączek L, Perkowska-Ptasińska A, Piecha G, Reichman T, Sanchez-Fueyo A, Tronina O, Wawrzynowicz-Syczewska M, Więcek A, Zieniewicz K, Halloran PF. The molecular phenotypes of injury, steatohepatitis, and fibrosis in liver transplant biopsies in the INTERLIVER study. Am J Transplant. 2022 Mar;22(3):909-926. doi: 10.1111/ajt.16890. Epub 2021 Dec 3.
Maharaj AD, Lubel J, Lam E, Clark PJ, Duncan O, George J, Jeffrey GP, Lipton L, Liu H, McCaughan G, Neo EL, Philip J, Strasser SI, Stuart K, Thompson A, Tibballs J, Tu T, Wallace MC, Wigg A, Wood M, Zekry A, Greenhill E, Ioannou LJ, Ahlenstiel G, Bowers K, Clarke SJ, Dev A, Fink M, Goodwin M, Karapetis CS, Levy MT, Muller K, O'Beirne J, Pryor D, Seow J, Shackel N, Tallis C, Butler N, Olynyk JK, Reed-Cox K, Zalcberg JR, Roberts SK. Monitoring quality of care in hepatocellular carcinoma: A modified Delphi consensus. Hepatol Commun. 2022 Nov;6(11):3260-3271. doi: 10.1002/hep4.2089. Epub 2022 Sep 25
Majumdar A, Tsochatzis EA. Binge drinking and fibrogenesis: More than just a hangover. Liver Int. 2022 Jan;42(1):6-8. doi: 10.1111/liv.15119.
Majumdar A, Tsochatzis EA. Non-invasive tests and advanced chronic liver disease in NAFLD: two steps forward and one step back? Gut. 2022 Jun;71(6):1236-1237. doi: 10.1136/gutjnl-2021-325994. Epub 2021 Sep 14.
Manuneedhi Cholan P, Morris S, Luo K, Chen J, Boland JA, McCaughan GW, Britton WJ, Oehlers SH. Transplantation of high fat fed mouse microbiota into zebrafish larvae identifies MyD88-dependent acceleration of hyperlipidaemia by Gram-positive cell wall components. Biofactors. 2022 Mar;48(2):329-341. doi: 10.1002/biof.1796. Epub 2021 Oct 19.
Marsh-Wakefield F, Ferguson AL, Liu K, Santhakumar C, McCaughan G, Palendira U. Approaches to spatially resolving the tumour immune microenvironment of hepatocellular carcinoma. Ther Adv Med Oncol. 2022 Jul 22;14:17588359221113270. doi: 10.1177/17588359221113270. eCollection 2022.
Méndez-Sánchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH, Sarin SK, Fabrellas N, Zelber-Sagi S, Fan JG, Shiha G, Targher G, Zheng MH, Chan WK, Vinker S, Kawaguchi T, Castera L, Yilmaz Y, Korenjak M, Spearman CW, Ungan M, Palmer M, El-Shabrawi M, Gruss HJ, Dufour JF, Dhawan A, Wedemeyer H, George J, Valenti L, Fouad Y, Romero-Gomez M, Eslam M; Global multi-stakeholder consensus on the redefinition of fatty liver disease. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol. 2022 May;7(5):388-390. doi: 10.1016/S2468-1253(22)00062-0. Epub 2022 Mar 3.
Nahar KJ, Marsh-Wakefield F, Rawson RV, Gide TN, Ferguson AL, Allen R, Quek C, da Silva IP, Tattersal S, Kiely CJ, Sandanayake N, Carlino MS, McCaughan G, Wilmott JS, Scolyer RA, Long GV, Menzies AM, Palendira U. Distinct pretreatment innate immune landscape and posttreatment T cell responses underlie immunotherapy-induced colitis. JCI Insight. 2022 Nov 8;7(21):e157839. doi: 10.1172/jci.insight.157839.
Nash E, Chetwood J, Strasser SI, Liu K. Drug-induced liver injury from herbal and dietary supplements: a problem in the East and West alike. Hepatol Int. 2022 Apr;16(2):477-478. doi: 10.1007/s12072-021-10289-1. Epub 2022 Jan 23.
Oguz Bolgi, Maria Silva-Garcia, Breyan Ross, Esther Pilla, Vijayalakshmi Kari, Markus Killisch, Melanie Spitzner, Nadine Stark, Christof Lenz, Konstantin Weiss, Laura Donzelli, Mark D. Gorrell, Marian Grade, Jan Riemer, Henning Urlaub, Matthias Dobbelstein, Robert Huber, Ruth Geiss-Friedlander 2022 Dipeptidyl peptidase 9 triggers BRCA2 degradation and promotes DNA-damage repair. EMBO Reports. Doi 10.15252/embr.202154136 
Patwala K, Prince DS, Celermajer Y, Alam W, Paul E, Strasser SI, McCaughan GW, Gow P, Sood S, Murphy E, Roberts S, Freeman E, Stratton E, Davison SA, Levy MT, Clark-Dickson M, Nguyen V, Bell S, Nicoll A, Bloom A, Lee AU, Ryan M, Howell J, Valaydon Z, Mack A, Liu K, Dev A. Lenvatinib for the treatment of hepatocellular carcinoma-a real-world multicenter Australian cohort study. Hepatol Int. 2022 Oct;16(5):1170-1178. doi: 10.1007/s12072-022-10398-5. Epub 2022 Aug 25.
Prince DS, Schlaphoff G, Davison SA, Huo YR, Xiang H, Chan MV, Lee AU, Thailakanathan C, Jebeili H, Rogan C, Al-Omary A, Gupta S, Lockart I, Tiwari N, Clark-Dickson M, Hillhouse JW, Laube R, Chang J, Nguyen V, Danta M, Cheng R, Strasser SI, Zekry A, Levy MT, Chan C, Liu K. Selective internal radiation therapy for hepatocellular carcinoma: A 15-year multicenter Australian cohort study. J Gastroenterol Hepatol. 2022 Nov;37(11):2173-2181. doi: 10.1111/jgh.15986. Epub 2022 Sep 2.PMID: 36031345
Rajadurai A, Zorron Cheng Tao Pu L, Cameron R, Tagkalidis P, Holt B, Bassan M, Gupta S, Croagh D, Swan M, Saxena P, Efthymiou M, Vaughan R, Chandran S; ANZEC. Endoscopic ultrasound-guided gallbladder and bile duct drainage with lumen apposing metal stent: A large multicenter cohort (with videos). J Gastroenterol Hepatol. 2022 Jan;37(1):179-189. doi: 10.1111/jgh.15688. Epub 2021 Oct 7.
Rodríguez-Perálvarez ML, Gómez-Orellana AM, Majumdar A, Bailey M, McCaughan GW, Gow P, Guerrero M, Taylor R, Guijo-Rubio D, Hervás-Martínez C, Tsochatzis EA. Development and validation of the Gender-Equity Model for Liver Allocation (GEMA) to prioritise candidates for liver transplantation: a cohort study. Lancet Gastroenterol Hepatol. 2022 Dec 14:S2468-1253(22)00354-5. doi: 10.1016/S2468-1253(22)00354-5. Online ahead of print.
Sagnella SM, White AL, Yeo D, Saxena P, van Zandwijk N, Rasko JEJ. Locoregional delivery of CAR-T cells in the clinic. Pharmacol Res. 2022 Aug;182:106329. doi: 10.1016/j.phrs.2022.106329. Epub 2022 Jun 27.
Salimi S, Pandya K, Davis RJ, Crawford M, Pulitano C, Strasser SI, McCaughan GW, Majumdar A, Liu K. Impact of Intensive Care Unit Discharge Delay on Liver Transplantation Outcomes. J Clin Med. 2022 May 2;11(9):2561. doi: 10.3390/jcm11092561.
Santhakumar C, Ormiston W, McCall JL, Bartlett A, Duncan D, Holden A. Portal vein embolization with absolute ethanol to induce hypertrophy of the future liver remnant. CVIR Endovasc. 2022 Jul 23;5(1):36. doi: 10.1186/s42155-022-00312-3.PMID: 35869399 Free PMC article.
Simone E Jaenisch, Abbott, CA, Gorrell, Mark D, Bampton, P, Butler, RN, Roger Yazbeck 2022 Circulating dipeptidyl peptidase activity is a potential biomarker for inflammatory bowel disease.  Clinical and Translational Gastroenterology doi 10.14309/ctg.0000000000000452  PMID 35060938 
Staudenmann D, Choi KKH, Kaffes AJ, Saxena P. Current endoscopic closure techniques for the management of gastrointestinal perforations. Ther Adv Gastrointest Endosc. 2022 Feb 27;15:26317745221076705. doi: 10.1177/26317745221076705. eCollection 2022 Jan-Dec.
Staudenmann D, Mudaliar S, Kaffes AJ, Saxena P. Lumen-apposing metal stents salvage that accidentally dislodged during a necrosectomy of a WON (with video). Endosc Ultrasound. 2022 Mar-Apr;11(2):147-148. doi: 10.4103/EUS-D-21-00054.
Tan N, Ngu N, Worland T, Lee T, Abrahams T, Pandya K, Freeman E, Hannah N, Gazelakis K, Madden RG, Lynch KD, Valaydon Z, Sood S, Dev A, Bell S, Thompson A, Ding J, Nicoll AJ, Liu K, Gow P, Lubel J, Kemp W, Roberts, SK, Majeed A. Epidemiology and outcomes of primary sclerosing cholangitis: an Australian multicentre retrospective cohort study. Hepatol Int. 2022;16:1094-1104.
Tavabie OD, McCaughan G, Aluvihare VR. Those Donor Leucocytes Again? This Time It's VITT! Liver Transpl. 2022 Feb;28(2):164-166. doi: 10.1002/lt.26372. Epub 2021 Dec 8.
Tran DL, Gibson H, Maiorana AJ, Verrall CE, Baker DW, Clode M, Lubans DR, Zannino D, Bullock A, Ferrie S, Briody J, Simm P, Wijesekera V, D'Almeida M, Gosbell SE, Davis GM, Weintraub R, Keech AC, Puranik R, Ugander M, Justo R, Zentner D, Majumdar A, Grigg L, Coombes JS, d'Udekem Y, Morris NR, Ayer J, Celermajer DS, Cordina R. Exercise Intolerance, Benefits, and Prescription for People Living With a Fontan Circulation: The Fontan Fitness Intervention Trial (F-FIT)-Rationale and Design. Front Pediatr. 2022 Jan 6;9:799125. doi: 10.3389/fped.2021.799125. eCollection 2021.
Yeo D, Bastian A, Strauss H, Saxena P, Grimison P, Rasko JEJ. Exploring the Clinical Utility of Pancreatic Cancer Circulating Tumor Cells. Int J Mol Sci. 2022 Jan 31;23(3):1671. doi: 10.3390/ijms23031671.
Yeo D, Giardina C, Saxena P, Rasko JEJ. The next wave of cellular immunotherapies in pancreatic cancer. Mol Ther Oncolytics. 2022 Feb 1;24:561-576. doi: 10.1016/j.omto.2022.01.010. eCollection 2022 Mar 17.
Yip TCF, Gill M, Wong GLH, Liu K. Management of hepatitis B virus reactivation due to treatment of COVID-19. Hepatol Int. 2022;16:257-268 
Yu V, Ebrahimi N, Cachalia T, Jacques A, Wyburn K, McCaughan GW, Dunkley S, Crawford MD, Pulitano C, Laurence JM. Combined Liver-Kidney Transplant for Juvenile Polycystic Kidney Disease and Concomitant Hereditary Factor V Deficiency. Exp Clin Transplant. 2022 Nov;20(11):1043-1045. doi: 10.6002/ect.2022.0229.
Yuen MF, Locarnini S, Lim TH, Strasser SI, Sievert W, Cheng W, Thompson AJ, Given BD, Schluep T, Hamilton J, Biermer M, Kalmeijer R, Beumont M, Lenz O, De Ridder F, Cloherty G, Ka-Ho Wong D, Schwabe C, Jackson K, Lai CL, Gish RG, Gane E. Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB. J Hepatol. 2022 Nov;77(5):1287-1298. doi: 10.1016/j.jhep.2022.07.010. Epub 2022 Jul 20.
Zhu S, Rao X, Qian Y, Chen J, Song R, Yan H, Yang X, Hu J, Wang X, Han Z, Zhu Y, Liu R, Jong-Leong Wong J, McCaughan GW, Zheng X. Liver Endothelial Heg Regulates Vascular/Biliary Network Patterning and Metabolic Zonation Via Wnt Signaling. Cell Mol Gastroenterol Hepatol. 2022;13(6):1757-1783. doi: 10.1016/j.jcmgh.2022.02.010. Epub 2022 Feb 22.